De novo CD5+ diffuse large b-cell lymphoma: A distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy

Leukemia and Lymphoma

Volumn 51, Issue 1, 2010, Pages 161-163

  Westin, Jason ^a   McLaughlin, Peter ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; METHOTREXATE; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADRENAL BIOPSY; ADULT; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LETTER; MULTIPLE CYCLE TREATMENT; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD5; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PREDNISOLONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 74949130882     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903324244     Document Type: Letter

References (9)

1. Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 1995;147: 207-216.
2. Kipps TJ. The CD5 B cell. Adv Immunol 1989;47:117-185.
3. Lydyard PM, Jewell AP, Jamin C, Youinou PY. CD5 B cells and B-cell malignancies. Curr Opin Hematol 1999;6:30-36.
4. Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5p diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002;99:815-821.
5. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;113:3896-3902.
6. Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5p diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica 2008;93:1195-1202.
7. Yamaguchi M, Ohno T, Oka K, et al. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol 1999;105:1133-1139.
8. Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008;19:1921-1926.
9. Hyo R, Tomita N, Takeuchi K, et al. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol 2009;Apr 8. [Epub ahead of print]. http://www3.interscience.wiley.com/ forwardlinking/?oid= 122302381